Clinical trial
Feasibility, Safety and Accuracy of Regadenoson-Atropine (REGAT) Stress Echocardiography for Diagnosis of Coronary Artery Disease: Angiographic Correlative Study
NCT00894179 is registered in ClinicalTrials.gov with Henry Ford Health System as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Feasibility, Safety and Accuracy of Regadenoson-Atropine (REGAT) Stress Echocardiography for Diagnosis of Coronary Artery Disease: Angiographic Correlative Study
- Lead sponsor
- Henry Ford Health System
- Phase
- Not applicable
- Overall status
- Terminated
- Start date
- October 31, 2009
- Completion date
- April 30, 2012
- Enrollment
- 45 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.